Liquidia Technologies (LQDA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from BTIG reiterated a Buy rating on the stock and has a $29.00 price target.
Julian Harrison has given his Buy rating due to a combination of factors surrounding Liquidia Technologies’ prospects with Yutrepia. The recent acceptance of the New Drug Application (NDA) for Yutrepia by the FDA, significantly faster than anticipated, and the assignment of a PDUFA date in May 2025, highlight the regulatory momentum behind the drug. This timing aligns closely with the expiration of exclusivity for a competing product, Tyvaso DPI, suggesting a strategic opening for Yutrepia’s market entry.
Furthermore, the promising results from the ASCENT study, where a high percentage of patients achieved therapeutic doses, indicate Yutrepia’s potential superiority over existing treatments. The planned transition study aims to further demonstrate Yutrepia’s advantages, potentially encouraging patient switching from nebulized Tyvaso. Additionally, the anticipated data release at the ATS conference is expected to reinforce Yutrepia’s efficacy, particularly in PH-ILD, positioning it as a leading option in its category. These factors collectively underpin Harrison’s optimistic outlook and Buy rating for LQDA.
Harrison covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Nektar Therapeutics, and Spyre Therapeutics. According to TipRanks, Harrison has an average return of 1.1% and a 38.31% success rate on recommended stocks.
In another report released on March 20, Raymond James also maintained a Buy rating on the stock with a $27.00 price target.